March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Bone Marrow Derived Dendritic Cells Prevent Corneal Allograft Rejection In The Rat
Author Affiliations & Notes
  • Thomas Ritter
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Mikhail Nosov
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Aideen Ryan
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Oliver Treacy
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Marese Cregg
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Gerry Fahy
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Mourice Morcos
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Lisa O'Flynn
    Medicine, Nt'l Univ of Ireland, Galway, Galway, Ireland
  • Footnotes
    Commercial Relationships  Thomas Ritter, None; Mikhail Nosov, None; Aideen Ryan, None; Oliver Treacy, None; Marese Cregg, None; Gerry Fahy, None; Mourice Morcos, None; Lisa O'Flynn, None
  • Footnotes
    Support  Science Foundation of Ireland (SFI 07/IN.1/B925)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6188. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas Ritter, Mikhail Nosov, Aideen Ryan, Oliver Treacy, Marese Cregg, Gerry Fahy, Mourice Morcos, Lisa O'Flynn; Bone Marrow Derived Dendritic Cells Prevent Corneal Allograft Rejection In The Rat. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6188.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the role of in-vitro generated Bone Marrow derived Dendritic Cells (BMDC) after glucocorticoid treatment on corneal allograft survival in the rat.

Methods: : BMDC were propagated from either Lewis (LEW) or Dark Agouti (DA) rat bone marrow precursors cells (1.5x106 cells/ml) in complete medium supplemented with rat GMCSF (5ng/µl) and IL-4 (5ng/µl). For glucocorticoid treatment of BMDCs, dexamethasone (Dexa) (10-6M) was added on d5 and d7 of a 10 day culture. BMDC and Dexa BMDC phenotype was characterised and analysed for expression of cell surface markers CD11b/c, MHC II, CD80, CD86 and His36 by flow cytometry. BMDC and Dexa BMDC antigen presenting cell function was examined in both antigen specific (Ovalbumin) and allo-antigen specific lymphocyte assays. Responder cells were analysed by FACS for proliferation and expression of lymphocyte activation markers CD25 or OX40. Moreover recall experiments were performed to study the mechanisms of immunomodulation in vivo. A fully allogeneic rat corneal transplantation model (DA to LEW) was used for in vivo studies. Day 10 syngeneic (LEW) alloantigen-pulsed or allogeneic (DA) Dexa BMDCs were harvested and 1x106cells/ml injected intravenously into LEW recipients 7 days prior to corneal transplant surgery. Graft survival, opacity and neovascularisation were monitored.

Results: : In vitro generated BMDCs have a semi-mature phenotype (moderate expression of MHC II, CD80 and CD86) and can be modified chemically to an immature phenotype with Dexa (low expression of MHC II, CD80 and CD86). BMDC and Dexa BMDC are capable of activating allogeneic lymphocytes but there is a reduced level of proliferation They can also efficiently present antigen and activate antigen specific T cells. In vivo untreated allogeneic control grafts were uniformly rejected (MST 13.8 ± 1.7d, n = 11). Injection of alloantigen-pulsed syngeneic BMDC had no effect on corneal allograft survival (MST 13 +/- 2.36d, n=6 and >30d n=1, spontaneous acceptance). In contrast, injection of allogeneic Dexa BMDC significantly prolonged corneal allograft survival (MST> 30d, n = 8). Opacity and neovascularisation scores were low in Dexa BMDC group compared to control groups.

Conclusions: : Glucocorticoid treatment of allogeneic BMDCs is a potent way of inducing tolerogenic cells and represents a potential therapeutic approach for the prevention of corneal allograft rejection.

Keywords: immune tolerance/privilege • transplantation • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×